Agency IQ

NOVEMBER 20, 2023

EPA issues white paper exploring the adoption of structured content and digital pesticide labels FDA delays enforcement of cosmetic product listing and facility registration, issues finalized guidance The EPA’s Office of Pesticide Programs (OPP) is in the developmental stage of creating a structured pesticide and digital pesticide label.

Regulations 40

Regulations Production International Compliance 40

Fierce BioTech

MAY 29, 2024

A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs New molecular formats are gaining momentum in today’s market. Read this white paper to learn more. lbarrick Wed, 05/29/2024 - 10:41 New molecular formats are gaining momentum in today’s market. Read this white paper to learn more.

Treatment 52

Treatment Disease Marketing Production 52

The Pharma Data

FEBRUARY 5, 2021

In this white paper, H. Download the white paper to understand: The different types of data within an organization, and the challenges they pose. How distributed reference and master data (RMD) can prevent redundancies, simplify management, and speed up time to market. Oberkampf, C. Senger and M.

Production 52

Production Marketing Research 52

The Pharma Data

NOVEMBER 11, 2020

White Papers / Tech Papers. Chewing gum as a dosage format for pharmaceutical applications in the OTC market stands out as a fast growing, innovative dosage format. Source link.

Pharmaceuticals 52

Pharmaceuticals Marketing 52

LifeSciVC

NOVEMBER 30, 2023

White papers were written and shared widely about these points. Several years into the post-bubble bear market, the public biotech sector has only contracted by 4.5% Bigger players eating smaller players” in the public markets just doesn’t happen with enough frequency to dent the broader number of publicly traded companies.

Marketing 112

Marketing Government Production 112

PPD

JULY 16, 2024

Our recent white paper explores the many ways in which a functional service provider (FSP) engagement delivers key pharmacovigilance (PV) capabilities necessary across the product life span and across different geographical regions.

Compliance 98

Compliance Regulations Production Trials 98

Conversations in Drug Development Trends

APRIL 4, 2024

While the ICH M10 guidelines are a step in the right direction, don’t forget these four key considerations: ICH M10 is only the starting point for international compliance, as certain markets may have other requirements. Select the right partner with experience meeting regulatory standards for all target markets.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

The Pharma Data

JULY 28, 2021

billion across its major markets in 2020 alone. These major markets represented 75% of Teva’s revenues in 2020. Across 9 major markets in Europe, Teva saved healthcare systems $9.6 biosimilars market continues to develop, savings are expected to grow and surpass $100 billion from 2020 to 2024. jobs and contributed $15.7

Marketing 52

Marketing Biosimilars Pharmaceuticals Drugs 52

The Pharma Data

JANUARY 18, 2021

Following Pharma IQ and SGK Health’s virtual masterclass in December 2020, this post-event report explores why authentic human-centric experiences are foundational to a pharma brands existence and the successful implementation of a digital marketing strategy. Redefine digital marketing in pharma with design thinking.

Marketing 52

Marketing Packaging Production 52

Conversations in Drug Development Trends

DECEMBER 20, 2023

You can learn more about biomarkers and how to use them in oncology studies in this white paper. Leveraging our experience on more than 100 studies in the past few years and our awareness of recent study design trends, we can help ensure your oncology program stays on track to market approval.

Clinical Trials 83

Clinical Trials Trials Pharmacokinetics FDA 83

The Pharma Data

NOVEMBER 26, 2020

Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market. Add bookmark. Download Your Copy. The benefits of developing a patient-centric clinical supply chain.

Clinical Trials 52

Clinical Trials Marketing Trials Clinical Supply 52

The Pharma Data

MARCH 20, 2021

In today’s Information Age, content marketing gets three times more leads than paid search advertising (Content Marketing Institute, 2017). While marketing teams know the value of marketing content, producing high-quality content can present a huge challenge to an in house marketing team. Choosing the Medium.

Marketing 52

Marketing Production International Science 52

PPD

OCTOBER 2, 2024

A recent white paper from the PPD™ clinical research business of Thermo Fisher Scientific details how these functions have evolved over the years, moving from capabilities that were previously built up and maintained in-house, to the multiple outsourcing models available today.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

The Pharma Data

SEPTEMBER 11, 2020

Dive into Medidata’s white paper to find out the best practices and new testing methods clinical trial sponsors are using to immerse patients into clinical trials for a better patient experience and for more enhanced data quality.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

PerkinElmer

FEBRUARY 18, 2021

Dr. Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

PPD

OCTOBER 12, 2023

There are over 2,000 CGTs currently being evaluated in clinical trials, with more than 200 in Phase III and 10-20 per year estimated to come to market by 2025. DOWNLOAD OUR WHITE PAPER Learn more about how PPD® Laboratory services can enhance your CGT projects.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

PPD

AUGUST 28, 2024

For pharmaceutical innovators and drug developers working to bring oncology therapies to market, patients are the “why” behind it all. As a leader in early phase development oncology trials, we are dedicated to using our vast experience to enhance the patient experience and successfully bring new therapies to market.

Trials 69

Trials Clinical Trials Drug Development Therapies 69

Conversations in Drug Development Trends

MARCH 7, 2024

For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”. Understanding the nuances of each pathway is crucial for small to midsize companies aiming to navigate the complexities of global clinical development successfully. appeared first on Worldwide Clinical Trials.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

H1 Blog

NOVEMBER 15, 2023

The compensation provided to KOLs should also be fair-market value for their time and effort, and not an inducement for them to prescribe or recommend specific products. For more information on how to build effective and compliant engagement plans, download our white paper: How AI Can Save Medical Affairs from Drowning in Data.

Compliance 59

Compliance Science Regulations Pharmaceutical Companies 59

PPD

DECEMBER 19, 2023

As biotech and biopharma companies seek out the best solutions in increasingly competitive talent markets – and adapt to new demands, priorities and challenges – it’s important to remember that not all FSP/FSO providers are alike. Ready to fuel more efficient drug development?

International 52

International Research Drug Development Pharmaceuticals 52

Drug Channels

FEBRUARY 23, 2021

For background, see Express Scripts + Prime Therapeutics: Our Four Takeaways From This Market Changing Deal. Payer-owned specialty pharmacies—via white, brown, and clear bagging—are trying to displace buy-and-bill distribution channels for provider-administered specialty drugs. The battle for specialty drug margin rages on.

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Independent Pharmacies 52

PPD

JULY 9, 2024

Biotech and biopharma companies, however, must do all of this in the face of wildly fluctuating workloads — particularly during the post-marketing phase. Download our white paper The post FSP Flex Hub Teams Maximize Efficiency Across Lifecycle Maintenance appeared first on PPD. Let’s connect.

Compliance 52

Compliance Production Clinical Research Marketing 52

PPD

JUNE 17, 2024

For example, a company bringing its first gene therapy candidate to market but lacking key expertise in running a gene therapy trial can start with an FSO model and transition to FSP arrangements as their internal expertise and experience grows.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

The Pharma Data

DECEMBER 28, 2020

Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.” Mr. Weild is a globally recognized leader in capital formation and capital markets structure. David Weild IV.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

The Pharma Data

AUGUST 11, 2020

How to improve pharma manufacturing operations from the ground up while maintaining product quality and speed to market. Pharma manufacturers are placing greater emphasis on process efficiency and cost containment measures as their focus shifts toward demand for cheaper generics and increasing products’ speed to market.

Production 52

Production Marketing Drugs 52

The Pharma Data

JANUARY 6, 2021

… Biopharmaceutical products represent up to 20 percent of the total pharmaceutical market and are growing at a rate of nearly eight percent annually. . DOWNLOAD TO LEARN MORE>>>> Source link.

Pharmaceuticals 52

Pharmaceuticals Production Marketing 52

The Pharma Data

JANUARY 7, 2021

While oral delivery route (62%) is still the most prevalent amongst marketed drug products, alternative adminstrations such as injection (22%), cutaneous, mucosal, inhalation, and others are making up a greater percentage as the industry works to improve bioavailability and subsequent efficacy.

Production 52

Production FDA Pharmaceuticals Marketing 52

The Pharma Data

SEPTEMBER 30, 2020

When doing business in fast-paced, hypercompetitive markets, it is imperative for organizations to ensure they have effective quality management processes and a system in place that reduces the risks of product launch delays. further information on how we process and monitor your personal data click. You can unsubscribe at any time.

Compliance 52

Compliance Production Marketing 52

The Pharma Data

NOVEMBER 16, 2020

To ensure the safety, quality and efficacy of a drug product prior to market roll out, it is critical life sciences companies can uphold the integrity and security of the data generated throughout an entire product’s lifecycle. For further information on how we process and monitor your personal data click here.

Science 52

Science Production Pharmaceuticals Marketing 52

The Pharma Data

SEPTEMBER 9, 2020

Transition to advanced analytics platforms to accelerate a product’s time-to-market. Heiner Oberkampf, Head of Data Governance at OSTHUS and learn how to: Digitally transform a drug development strategy. Improve productivity and data integration by driving the use of semantic systems.

Production 52

Production Laboratories Compliance Government 52

Agency IQ

MAY 10, 2024

BY LAURA DIANGELO, MPH | MAY 9, 2024 9:20 PM CDT Background: Servicing and remanufacturing – and why the difference matters Medical device regulatory oversight does not end at the point of market access, nor do the manufacturing requirements after distribution. Remanufacturing versus servicing: What it is and why it matters.

FDA 40

FDA Regulations Compliance Production 40

The Pharma Data

MARCH 20, 2021

In all processes where dissolved CO2 plays a key role in the metabolism, insitu CO2 measurement allows a faster scale-up during process development and finally a faster time to market for new products. . Use of the CO2 sensor InPro 5000 .

Bioinformatics 52

Bioinformatics Laboratories Production Engineering 52

Agency IQ

APRIL 12, 2024

ACRO’s white paper also highlights the potential for “enhanced efficiency, long-term cost savings, and faster collection of data” through risk-based monitoring and other data collection efficiencies. This also may include advice on the use of DHTs in clinical trials or post-market studies subject to the FDA’s regulation.”

Regulations 40

Regulations Trials Clinical Trials Science 40

Agency IQ

NOVEMBER 10, 2023

Read AgencyIQ’s analysis of FDA’s QMM White Paper here.] By promoting improved product and process capability, CDER hopes to reduce the number of product shortages caused by quality-related issues. Another initiative established by OPQ for product quality is known as Knowledge Aided Assessment and Structured Application (KASA).

Pharmaceuticals 40

Pharmaceuticals Small Molecule Science FDA 40

Agency IQ

JULY 7, 2023

Read AgencyIQ’s analysis of FDA’s QMM White Paper here.] despite holding onto 40% of the total market share of manufacturing facilities— has a position of strength that is slowly eroding. In contrast, the market share of domestically located manufacturing sites decreased one percentage point from 42.9%

Pharmaceuticals 40

Pharmaceuticals Science FDA Production 40

Agency IQ

JULY 21, 2023

In parallel, FOCR developed a white paper that provided an overview of the potential regulatory applications for ctDNA in oncology. The paper, published in November 2021, primarily focused on the potential for ctDNA to serve as an early endpoint. completing confirmatory trials).

FDA 40

FDA Clinical Trials Treatment Trials 40

FDA Law Blog: Biosimilars

APRIL 8, 2024

Department of Health and Human Services (HHS) recently published a White Paper on Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States —with input from several HHS stakeholders, including FDA, CMS, and the Administration for Strategic Preparedness and Response. By Kalie E.

Drugs 59

Drugs FDA Hospitals Government 59